Paper322649
Timolol, dose response and duration of action.
Zimmerman TJ and 1 other. Arch Ophthalmol, 1977. Cited by 242 papers, by iCite.
Cite this record
ConductScience Library. Timolol, dose response and duration of action. Papers, record 322649. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/322649
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glaucoma | Major topic |
| Propanolamines | Major topic |
| Timolol | Major topic |
| Adult | |
| Clinical Trials as Topic | |
| Dose-Response Relationship, Drug | |
| Humans | |
| Intraocular Pressure | |
| Ophthalmic Solutions | |
| Placebos | |
| Time Factors |
Source PubMed
Cited by47
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 242 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41471311 | Challenge of Corneal Ulcer Healing: A Novel Conceptual Framework, the "Triad" of Corneal Ulcer Healing/Corneal Neovascularization/Intraocular Pressure, and Avascular Tendon Healing, for Evaluation of Corneal Ulcer Therapy, Therapy of Neovascularization, Glaucoma Therapy, and Pentadecapeptide BPC 157 Efficacy. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41471311 | PubMed |
| 38399328 | Chemical Insights into Topical Agents in Intraocular Pressure Management: From Glaucoma Etiopathology to Therapeutic Approaches. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38399328 | PubMed |
| 37513963 | Stable Gastric Pentadecapeptide BPC 157-Possible Novel Therapy of Glaucoma and Other Ocular Conditions. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37513963 | PubMed |
| 35130584 | Lab-on-a-Contact Lens: Recent Advances and Future Opportunities in Diagnostics and Therapeutics. | Adv Mater | 2022 | https://conductscience.org/library/papers/35130584 | PubMed |
| 32513257 | Beta-adrenergic antagonist for the healing of chronic diabetic foot ulcers: study protocol for a prospective, randomized, double-blinded, controlled and parallel-group study. | Trials | 2020 | https://conductscience.org/library/papers/32513257 | PubMed |
| 30794789 | Effect of Timolol on Aqueous Humor Outflow Facility in Healthy Human Eyes. | Am J Ophthalmol | 2019 | https://conductscience.org/library/papers/30794789 | PubMed |
| 28480761 | Topical treatment of glaucoma: established and emerging pharmacology. | Expert Opin Pharmacother | 2017 | https://conductscience.org/library/papers/28480761 | PubMed |
| 28399267 | Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability. | Invest Ophthalmol Vis Sci | 2017 | https://conductscience.org/library/papers/28399267 | PubMed |
| 27471373 | The intraocular pressure-lowering properties of intravenous paracetamol. | Clin Ophthalmol | 2016 | https://conductscience.org/library/papers/27471373 | PubMed |
| 27041984 | Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose-response phenomenon. | Clin Ophthalmol | 2016 | https://conductscience.org/library/papers/27041984 | PubMed |
| 25349811 | Fixed combination of latanoprost and timolol vs the individual components for primary open angle glaucoma and ocular hypertension: a systematic review and meta-analysis. | Int J Ophthalmol | 2014 | https://conductscience.org/library/papers/25349811 | PubMed |
| 21892247 | Effect of hydrophobic and hydrophilic additives on sol-gel transition and release behavior of timolol maleate from polycaprolactone-based hydrogel. | Colloid Polym Sci | 2011 | https://conductscience.org/library/papers/21892247 | PubMed |
| 20040958 | Recent advances in pharmacotherapy of glaucoma. | Indian J Pharmacol | 2008 | https://conductscience.org/library/papers/20040958 | PubMed |
| 19668385 | Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%). | Clin Ophthalmol | 2008 | https://conductscience.org/library/papers/19668385 | PubMed |
| 17041807 | Topical drug therapy in glaucoma. | Wien Med Wochenschr | 2006 | https://conductscience.org/library/papers/17041807 | PubMed |
| 16532287 | Evolving paradigms in the medical treatment of glaucoma. | Int Ophthalmol | 2004 | https://conductscience.org/library/papers/16532287 | PubMed |
| 12034694 | Should beta blockers be abandoned as initial monotherapy in chronic open angle glaucoma? The controversy. | Br J Ophthalmol | 2002 | https://conductscience.org/library/papers/12034694 | PubMed |
| 10776828 | Pharmacological therapy for glaucoma: a review. | Drugs | 2000 | https://conductscience.org/library/papers/10776828 | PubMed |
| 10600045 | Efficacy and adverse effects of medications used in the treatment of glaucoma. | Drugs Aging | 1999 | https://conductscience.org/library/papers/10600045 | PubMed |
| 9112163 | Ocular hypotensive effect of sublingual administration of timolol. | Int Ophthalmol | 1996 | https://conductscience.org/library/papers/9112163 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/322649
GET https://conductscience.org/api/papers/v1/322649/cited_by?page=2